AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05511870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil Nasal Spray 70mg
Description: Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study NCT05511870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study NCT06485921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic compression
Description: Participants will received a total of 12 treatment sessions over 6 weeks, with 2 sessions per week.
Study NCT06485921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument assisted soft tissue mobilization Group
Description: Participants will received a total of 12 treatment sessions over 6 weeks, with 2 sessions per week.
Study NCT06485921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and workplace modifications
Description: Participants will receive stretching and strengthening exercises for neck and scapular stabilizer muscles as a 6-week home program.
Study NCT06485921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and workplace modifications
Description: Participants will receive stretching and strengthening exercises for neck and scapular stabilizer muscles as a 6-week home program.
Study NCT04947007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrogen chloride (HCl) 0.025 % in 15+15 ML Injection
Description: In this group, US guided suprascapulary and axillary block will be performed with 15 ml +15 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
Study NCT04947007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.025 % in 10+10 ML Injection
Description: In this group, US guided suprascapulary and axillary block will be performed with 10 ml +10 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
Study NCT04947007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.025 % in 5+5 ML Injection
Description: In this group, US guided suprascapulary and axillary block will be performed with 5 ml +5 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
Study NCT04947007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic solution
Description: In this group, US guided suprascapulary and axillary block will be performed with isotonic solution
Study NCT06213025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based Educational program promoting response and willingness to handle elderly
Description: promote the response and willingness of gerontological nurses in handling elderly abuse cases. By employing a rigorous experimental design, this research seeks to contribute evidence-based insights that can inform educational strategies to empower nurses in safeguarding the well-being of elderly individuals.
Study NCT05641272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3,000 MM09
Description: Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy.
Study NCT05641272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9,000 MM09
Description: Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.
Study NCT05641272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sublingual
Description: The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.
Study NCT04904432 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: PLIN1 gene sequencing
Description: One supplementary blood sample will be taken (compare to classical ACS treatment and follow up) to realize genetic analyse of PLIN1 gene, looking for mutations
Study NCT04199780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation (tDCS), stimulates specific areas of the brain via electric current passed through electrodes placed on the scalp. During tDCS, low amplitude direct currents penetrates the skull to enter the brain and modulates neuronal activity.
Study NCT04199780 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation (tDCS), stimulates specific areas of the brain via electric current passed through electrodes placed on the scalp. During tDCS, low amplitude direct currents penetrates the skull to enter the brain and modulates neuronal activity.
Study NCT04199780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral (CB) intervention
Description: CBI generally consist of cognitive coping strategies (e.g., distraction, relabeling, reducing pain-catastrophizing) and self-management (e.g., relaxation strategies, guided imagery) designed to enhance perceived control and reduce sympathetic nervous system tone.
Study NCT04199780 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive-Behavioral (CB) intervention
Description: CBI generally consist of cognitive coping strategies (e.g., distraction, relabeling, reducing pain-catastrophizing) and self-management (e.g., relaxation strategies, guided imagery) designed to enhance perceived control and reduce sympathetic nervous system tone.
Study NCT05362188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide Topical
Description: Patients with discoid lupus erythematosus (face \& scalp) will be given topical nicotinamide in two concentrations (2\&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream \& gel).
Study NCT05362188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide Topical
Description: Patients with discoid lupus erythematosus (face \& scalp) will be given topical nicotinamide in two concentrations (2\&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream \& gel).
Study NCT04831736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Study NCT04831736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching equal dose of saline placebo will be administered intravenously while the participant is recovering in the PACU.
Study NCT06533241 — intervention group
Intervention type: PROCEDURE
Intervention: renal biopsy
Description: percutaneous renal biopsy procedure
Study NCT05302466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gymnastics plus silicon dental bite pad
Description: Gymnastics (see below) plus dental bite pads. The dental bite pads TJ Motion (BELY Balance GmbH \& Co. KG, Weisendorf, Germany) are made of medical silicone. Accordingly, they are BPA- and latex-free, odourless, tasteless and dimensionally stable. The splints are placed on the back molars of the lower jaw and remain in this position in the mouth for 3 minutes during the exercise. After use, the splints are rinsed with water and placed dry in the corresponding storage box.
Study NCT05302466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gymnastics only
Description: Gymnastics, which are completed daily (7x/week), each consist of three to six exercises and have a total duration of three minutes. The gymnastic programme contain low-intensity exercises from functional gymnastic or physiotherapy.
Study NCT05806801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MICT Exercise
Description: Subjects randomized into this group will complete a moderate intensity continuous exercise 4 days/week.
Study NCT05806801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Exercise (Control)
Description: Subjects randomized into this group will remain sedentary throughout the duration of the study.
Study NCT05498259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib 150mg qd PO
Study NCT05498259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle
Study NCT05498259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP-like Regimen
Description: cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
Study NCT05438290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPCP
Description: topical immunomodulator
Study NCT05474560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg/day) plus lifestyle intervention
Description: participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Study NCT05474560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg plus lifestyle intervention
Description: participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Study NCT05474560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life style intervention
Description: According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Study NCT04826185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMB-1018972
Description: Modified release (MR) oral tablet
Study NCT04826185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral tablet
Study NCT06477315 — intervention group
Intervention type: OTHER
Intervention: survey
Description: telephone surveys
Study NCT06274216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 5000 IU of vitamin D3 orally every day for 12 weeks
Study NCT06274216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E 400
Description: 400mg of vitamin E orally every day for 12 weeks
Study NCT06355960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP Dexmedetomidine
Description: Dexmedetomidine (Precedex) loadings of 1 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
Study NCT06355960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP B
Description: Dexmedetomidine (Precedex) loadings of 0.5 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
Study NCT06355960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP C
Description: Dexmedetomidine (Precedex) loadings of 0.25 μg/kg, then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
Study NCT05617859 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib mesylate capsule
Description: Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight >60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
Study NCT04741685 — intervention group
Intervention type: DEVICE
Intervention: TTSX2
Description: Treatment with Tandem T Slim X2 with Basal IQ
Study NCT04741685 — intervention group
Intervention type: DEVICE
Intervention: MM640G
Description: Treatment with Medtronic Minimed 640G with Smartguard
Study NCT06271421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NanoTherm therapy
Description: Cyclic hyperthermia in patients with recurrent glioblastoma multiforme, who underwent implantation of iron oxide nanoparticles.
Study NCT06271421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glioma Resection
Description: Removal of brain tumor - gross total ressection
Study NCT06271421 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Glioma Resection
Description: Removal of brain tumor - gross total ressection
Study NCT06271421 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy according to Stupp protocol
Description: The total dose according to the Stupp protocol is 60 Gy and is administered in fractions of 2 Gy per day for 5 days (Monday to Friday) for 6 weeks.
Study NCT06271421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy according to Stupp protocol
Description: Temozolomide is used during radiotherapy: 75 mg/m2 of body surface area per day for 7 days a week. After the completion of radiotherapy, temozolomide is used as adjuvant therapy - 6 cycles of 150-200 mg/m2 of body surface area for 5 days every 28 days.
Study NCT05508282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Bees app and children's book to enhance parent-infant reading quality (0-2 month visit)
Description: The reading intervention will be provided at the baseline clinic well-visit (0-2 months), and is based on the SHARE/STEP approach.
Study NCT05508282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Bees app and children's book to encourage alternatives to digital media (6-month visit)
Description: The digital media (screen time) intervention will be provided at the 6-month clinic well-visit and is based on Baby Unplugged materials (book and app content).
Study NCT05697484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: educational game
Description: Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, an access to the mobile game after a simple training for game usage. Both groups will be followed for a period of 3 months.~The mobile game is planned to have the following design:~1. Game will be presented in Arabic language.~2. The game will consist of four levels. a. At the beginning of each level there will be an educational video that the patient must watch in order to be allowed to start the level.
Study NCT05537337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Intervention
Description: The multicomponent intervention consists of the following components (already described in the detailed description section):~1. Food labels (with the summary of healthiness of shopping baskets \& targets)~2. Ordering~3. Within Group Healthier Substitution
Study NCT05260710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Intervention
Description: Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~+~Continuing education activities: video classes and discussions of complex cases.
Study NCT05881668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-EV
Description: 10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
Study NCT05734846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lenses (control fitting approach)
Description: Daily wear multifocal lenses for 1 week
Study NCT05734846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lenses (test fitting approach)
Description: Daily wear multifocal lenses for 1 week
Study NCT05471219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces
Description: Informed consent was obtained from the mothers to take pictures of newborns who were delivered in the delivery room, routinely cared for, dressed and breastfed by the researcher. A 10-minute visual track was created to be turned into a slide from approximately 70 photos. Vaginal examination was performed between the 4th and 6th minutes while focusing on this visual trace.
Study NCT05509907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedi@ctivity Analysis and Tracking Mobile Applications and Web Platform
Description: Pedi@ctivity Analysis Mobile Application and than Pedi@ctivity Analysis and Tracking Web Platform synchronized with the Pedi@ctivity Tracking Mobile Application, will be developed. The collected data will be analyzed with statistical methods and models using artificial intelligence algorithms will be created. According to the evaluations, physical activity and exercise videos and programs will be prepared and uploaded to web platform. Programs will include stretching, strengthening, balance, aerobic, calisthenic exercises and aerobic dance. The exercise and physical activity program will also be synchronized with the Pedi@ctivity Tracking Mobile Application and the smart watch. Pedi@ctivity Mobile Applications will provide health parameters from the smart watch, suggestions suitable for the exercise and physical activity program, and motivational feedback. Each adolescent will be included in a 3-month program. After the 3-month all evaluations at the beginning will be repeated.
Study NCT06399380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual mobilization of the carpal bones.
Description: The mobilization of the carpal bones will be done in the following way: patient in supine position, with elbow flexion of approximately 90º, so that the forearm and wrist are almost vertical. The examiner positions the thumb on the dorsal aspect of the scaphoid and trapezius, and the index finger on the dorsal aspect of the piriformis and hamate. Next, a manual ventral force is applied until the resistance of the wrist tissues is felt for 30 seconds. The technique will be repeated 5 times, with a 10-second rest between each application.
Study NCT06399380 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A technique will be performed that will have no effect; the hands will be placed at a point that will not be the carpal tunnel, such as the forearm.
Study NCT05369897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR training
Description: The intervention group will receive cognitive training through VR headsets three times a week for 12 weeks. The intervention will be delivered in a virtual setting using images and music. The participants will be allowed to select the type of music and virtual environment during the intervention. The intervention will include four modules targeting attention and working memory through immersive VR.
Study NCT05369897 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VR activity
Description: High-quality 360º images and videos from natural environments, such as a relaxing mountain environment. The participants in the control group will not receive cognitive training.
Study NCT04750395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Solution
Description: Oral transmucosal haloperidol solution 2.5mg
Study NCT04750395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Tablets
Description: Oral transmucosal olanzapine tablet 5.0mg
Study NCT05912647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTM
Description: Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.
Study NCT05912647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW
Description: Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one \~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive \~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.
Study NCT05976321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.
Study NCT05020158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention
Description: A psychosocial family-based intervention that is designed to give support to an entire family when a child has life-threatening illness.
Study NCT06292845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical application of a fluorescent imaging agent
Description: The fluorescent imaging agent will be topically applied only onto the resection planes of the freshly resected tumor specimen.~During incubation and after each washing steps, visible light and fluorescent overlay images will be acquired using a fluorescence sensitive camera system.
Study NCT05397600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost Ophthalmic
Description: Eyedrops
Study NCT05397600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic
Description: Eyedrops